Compassionate Use of Remdesivir for Patients with Severe Covid-19
Identifieur interne : 001301 ( Pmc/Corpus ); précédent : 001300; suivant : 001302Compassionate Use of Remdesivir for Patients with Severe Covid-19
Auteurs : Jonathan Grein ; Norio Ohmagari ; Daniel Shin ; George Diaz ; Erika Asperges ; Antonella Castagna ; Torsten Feldt ; Gary Green ; Margaret L. Green ; François-Xavier Lescure ; Emanuele Nicastri ; Rentaro Oda ; Kikuo Yo ; Eugenia Quiros-Roldan ; Alex Studemeister ; John Redinski ; Seema Ahmed ; Jorge Bernett ; Daniel Chelliah ; Danny Chen ; Shingo Chihara ; Stuart H. Cohen ; Jennifer Cunningham ; Antonella D Rminio Monforte ; Saad Ismail ; Hideaki Kato ; Giuseppe Lapadula ; Erwan L Er ; Toshitaka Maeno ; Sumit Majumder ; Marco Massari ; Marta Mora-Rillo ; Yoshikazu Mutoh ; Duc Nguyen ; Ewa Verweij ; Alexander Zoufaly ; Anu O. Osinusi ; Adam Dezure ; Yang Zhao ; Lijie Zhong ; Anand Chokkalingam ; Emon Elboudwarej ; Laura Telep ; Leighann Timbs ; Ilana Henne ; Scott Sellers ; Huyen Cao ; Susanna K. Tan ; Lucinda Winterbourne ; Polly Desai ; Robertino Mera ; Anuj Gaggar ; Robert P. Myers ; Diana M. Brainard ; Richard Childs ; Timothy FlaniganSource :
- The New England Journal of Medicine [ 0028-4793 ] ; 2020.
Abstract
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.
We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day.
Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.
In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)
Url:
DOI: 10.1056/NEJMoa2007016
PubMed: NONE
PubMed Central: 7169476
Links to Exploration step
PMC:7169476Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Compassionate Use of Remdesivir for Patients with Severe Covid-19</title><author><name sortKey="Grein, Jonathan" sort="Grein, Jonathan" uniqKey="Grein J" first="Jonathan" last="Grein">Jonathan Grein</name></author><author><name sortKey="Ohmagari, Norio" sort="Ohmagari, Norio" uniqKey="Ohmagari N" first="Norio" last="Ohmagari">Norio Ohmagari</name></author><author><name sortKey="Shin, Daniel" sort="Shin, Daniel" uniqKey="Shin D" first="Daniel" last="Shin">Daniel Shin</name></author><author><name sortKey="Diaz, George" sort="Diaz, George" uniqKey="Diaz G" first="George" last="Diaz">George Diaz</name></author><author><name sortKey="Asperges, Erika" sort="Asperges, Erika" uniqKey="Asperges E" first="Erika" last="Asperges">Erika Asperges</name></author><author><name sortKey="Castagna, Antonella" sort="Castagna, Antonella" uniqKey="Castagna A" first="Antonella" last="Castagna">Antonella Castagna</name></author><author><name sortKey="Feldt, Torsten" sort="Feldt, Torsten" uniqKey="Feldt T" first="Torsten" last="Feldt">Torsten Feldt</name></author><author><name sortKey="Green, Gary" sort="Green, Gary" uniqKey="Green G" first="Gary" last="Green">Gary Green</name></author><author><name sortKey="Green, Margaret L" sort="Green, Margaret L" uniqKey="Green M" first="Margaret L." last="Green">Margaret L. Green</name></author><author><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name></author><author><name sortKey="Nicastri, Emanuele" sort="Nicastri, Emanuele" uniqKey="Nicastri E" first="Emanuele" last="Nicastri">Emanuele Nicastri</name></author><author><name sortKey="Oda, Rentaro" sort="Oda, Rentaro" uniqKey="Oda R" first="Rentaro" last="Oda">Rentaro Oda</name></author><author><name sortKey="Yo, Kikuo" sort="Yo, Kikuo" uniqKey="Yo K" first="Kikuo" last="Yo">Kikuo Yo</name></author><author><name sortKey="Quiros Roldan, Eugenia" sort="Quiros Roldan, Eugenia" uniqKey="Quiros Roldan E" first="Eugenia" last="Quiros-Roldan">Eugenia Quiros-Roldan</name></author><author><name sortKey="Studemeister, Alex" sort="Studemeister, Alex" uniqKey="Studemeister A" first="Alex" last="Studemeister">Alex Studemeister</name></author><author><name sortKey="Redinski, John" sort="Redinski, John" uniqKey="Redinski J" first="John" last="Redinski">John Redinski</name></author><author><name sortKey="Ahmed, Seema" sort="Ahmed, Seema" uniqKey="Ahmed S" first="Seema" last="Ahmed">Seema Ahmed</name></author><author><name sortKey="Bernett, Jorge" sort="Bernett, Jorge" uniqKey="Bernett J" first="Jorge" last="Bernett">Jorge Bernett</name></author><author><name sortKey="Chelliah, Daniel" sort="Chelliah, Daniel" uniqKey="Chelliah D" first="Daniel" last="Chelliah">Daniel Chelliah</name></author><author><name sortKey="Chen, Danny" sort="Chen, Danny" uniqKey="Chen D" first="Danny" last="Chen">Danny Chen</name></author><author><name sortKey="Chihara, Shingo" sort="Chihara, Shingo" uniqKey="Chihara S" first="Shingo" last="Chihara">Shingo Chihara</name></author><author><name sortKey="Cohen, Stuart H" sort="Cohen, Stuart H" uniqKey="Cohen S" first="Stuart H." last="Cohen">Stuart H. Cohen</name></author><author><name sortKey="Cunningham, Jennifer" sort="Cunningham, Jennifer" uniqKey="Cunningham J" first="Jennifer" last="Cunningham">Jennifer Cunningham</name></author><author><name sortKey="D Rminio Monforte, Antonella" sort="D Rminio Monforte, Antonella" uniqKey="D Rminio Monforte A" first="Antonella" last="D Rminio Monforte">Antonella D Rminio Monforte</name></author><author><name sortKey="Ismail, Saad" sort="Ismail, Saad" uniqKey="Ismail S" first="Saad" last="Ismail">Saad Ismail</name></author><author><name sortKey="Kato, Hideaki" sort="Kato, Hideaki" uniqKey="Kato H" first="Hideaki" last="Kato">Hideaki Kato</name></author><author><name sortKey="Lapadula, Giuseppe" sort="Lapadula, Giuseppe" uniqKey="Lapadula G" first="Giuseppe" last="Lapadula">Giuseppe Lapadula</name></author><author><name sortKey="L Er, Erwan" sort="L Er, Erwan" uniqKey="L Er E" first="Erwan" last="L Er">Erwan L Er</name></author><author><name sortKey="Maeno, Toshitaka" sort="Maeno, Toshitaka" uniqKey="Maeno T" first="Toshitaka" last="Maeno">Toshitaka Maeno</name></author><author><name sortKey="Majumder, Sumit" sort="Majumder, Sumit" uniqKey="Majumder S" first="Sumit" last="Majumder">Sumit Majumder</name></author><author><name sortKey="Massari, Marco" sort="Massari, Marco" uniqKey="Massari M" first="Marco" last="Massari">Marco Massari</name></author><author><name sortKey="Mora Rillo, Marta" sort="Mora Rillo, Marta" uniqKey="Mora Rillo M" first="Marta" last="Mora-Rillo">Marta Mora-Rillo</name></author><author><name sortKey="Mutoh, Yoshikazu" sort="Mutoh, Yoshikazu" uniqKey="Mutoh Y" first="Yoshikazu" last="Mutoh">Yoshikazu Mutoh</name></author><author><name sortKey="Nguyen, Duc" sort="Nguyen, Duc" uniqKey="Nguyen D" first="Duc" last="Nguyen">Duc Nguyen</name></author><author><name sortKey="Verweij, Ewa" sort="Verweij, Ewa" uniqKey="Verweij E" first="Ewa" last="Verweij">Ewa Verweij</name></author><author><name sortKey="Zoufaly, Alexander" sort="Zoufaly, Alexander" uniqKey="Zoufaly A" first="Alexander" last="Zoufaly">Alexander Zoufaly</name></author><author><name sortKey="Osinusi, Anu O" sort="Osinusi, Anu O" uniqKey="Osinusi A" first="Anu O." last="Osinusi">Anu O. Osinusi</name></author><author><name sortKey="Dezure, Adam" sort="Dezure, Adam" uniqKey="Dezure A" first="Adam" last="Dezure">Adam Dezure</name></author><author><name sortKey="Zhao, Yang" sort="Zhao, Yang" uniqKey="Zhao Y" first="Yang" last="Zhao">Yang Zhao</name></author><author><name sortKey="Zhong, Lijie" sort="Zhong, Lijie" uniqKey="Zhong L" first="Lijie" last="Zhong">Lijie Zhong</name></author><author><name sortKey="Chokkalingam, Anand" sort="Chokkalingam, Anand" uniqKey="Chokkalingam A" first="Anand" last="Chokkalingam">Anand Chokkalingam</name></author><author><name sortKey="Elboudwarej, Emon" sort="Elboudwarej, Emon" uniqKey="Elboudwarej E" first="Emon" last="Elboudwarej">Emon Elboudwarej</name></author><author><name sortKey="Telep, Laura" sort="Telep, Laura" uniqKey="Telep L" first="Laura" last="Telep">Laura Telep</name></author><author><name sortKey="Timbs, Leighann" sort="Timbs, Leighann" uniqKey="Timbs L" first="Leighann" last="Timbs">Leighann Timbs</name></author><author><name sortKey="Henne, Ilana" sort="Henne, Ilana" uniqKey="Henne I" first="Ilana" last="Henne">Ilana Henne</name></author><author><name sortKey="Sellers, Scott" sort="Sellers, Scott" uniqKey="Sellers S" first="Scott" last="Sellers">Scott Sellers</name></author><author><name sortKey="Cao, Huyen" sort="Cao, Huyen" uniqKey="Cao H" first="Huyen" last="Cao">Huyen Cao</name></author><author><name sortKey="Tan, Susanna K" sort="Tan, Susanna K" uniqKey="Tan S" first="Susanna K." last="Tan">Susanna K. Tan</name></author><author><name sortKey="Winterbourne, Lucinda" sort="Winterbourne, Lucinda" uniqKey="Winterbourne L" first="Lucinda" last="Winterbourne">Lucinda Winterbourne</name></author><author><name sortKey="Desai, Polly" sort="Desai, Polly" uniqKey="Desai P" first="Polly" last="Desai">Polly Desai</name></author><author><name sortKey="Mera, Robertino" sort="Mera, Robertino" uniqKey="Mera R" first="Robertino" last="Mera">Robertino Mera</name></author><author><name sortKey="Gaggar, Anuj" sort="Gaggar, Anuj" uniqKey="Gaggar A" first="Anuj" last="Gaggar">Anuj Gaggar</name></author><author><name sortKey="Myers, Robert P" sort="Myers, Robert P" uniqKey="Myers R" first="Robert P." last="Myers">Robert P. Myers</name></author><author><name sortKey="Brainard, Diana M" sort="Brainard, Diana M" uniqKey="Brainard D" first="Diana M." last="Brainard">Diana M. Brainard</name></author><author><name sortKey="Childs, Richard" sort="Childs, Richard" uniqKey="Childs R" first="Richard" last="Childs">Richard Childs</name></author><author><name sortKey="Flanigan, Timothy" sort="Flanigan, Timothy" uniqKey="Flanigan T" first="Timothy" last="Flanigan">Timothy Flanigan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmc">7169476</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169476</idno><idno type="RBID">PMC:7169476</idno><idno type="doi">10.1056/NEJMoa2007016</idno><idno type="pmid">NONE</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">001301</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001301</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Compassionate Use of Remdesivir for Patients with Severe Covid-19</title><author><name sortKey="Grein, Jonathan" sort="Grein, Jonathan" uniqKey="Grein J" first="Jonathan" last="Grein">Jonathan Grein</name></author><author><name sortKey="Ohmagari, Norio" sort="Ohmagari, Norio" uniqKey="Ohmagari N" first="Norio" last="Ohmagari">Norio Ohmagari</name></author><author><name sortKey="Shin, Daniel" sort="Shin, Daniel" uniqKey="Shin D" first="Daniel" last="Shin">Daniel Shin</name></author><author><name sortKey="Diaz, George" sort="Diaz, George" uniqKey="Diaz G" first="George" last="Diaz">George Diaz</name></author><author><name sortKey="Asperges, Erika" sort="Asperges, Erika" uniqKey="Asperges E" first="Erika" last="Asperges">Erika Asperges</name></author><author><name sortKey="Castagna, Antonella" sort="Castagna, Antonella" uniqKey="Castagna A" first="Antonella" last="Castagna">Antonella Castagna</name></author><author><name sortKey="Feldt, Torsten" sort="Feldt, Torsten" uniqKey="Feldt T" first="Torsten" last="Feldt">Torsten Feldt</name></author><author><name sortKey="Green, Gary" sort="Green, Gary" uniqKey="Green G" first="Gary" last="Green">Gary Green</name></author><author><name sortKey="Green, Margaret L" sort="Green, Margaret L" uniqKey="Green M" first="Margaret L." last="Green">Margaret L. Green</name></author><author><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name></author><author><name sortKey="Nicastri, Emanuele" sort="Nicastri, Emanuele" uniqKey="Nicastri E" first="Emanuele" last="Nicastri">Emanuele Nicastri</name></author><author><name sortKey="Oda, Rentaro" sort="Oda, Rentaro" uniqKey="Oda R" first="Rentaro" last="Oda">Rentaro Oda</name></author><author><name sortKey="Yo, Kikuo" sort="Yo, Kikuo" uniqKey="Yo K" first="Kikuo" last="Yo">Kikuo Yo</name></author><author><name sortKey="Quiros Roldan, Eugenia" sort="Quiros Roldan, Eugenia" uniqKey="Quiros Roldan E" first="Eugenia" last="Quiros-Roldan">Eugenia Quiros-Roldan</name></author><author><name sortKey="Studemeister, Alex" sort="Studemeister, Alex" uniqKey="Studemeister A" first="Alex" last="Studemeister">Alex Studemeister</name></author><author><name sortKey="Redinski, John" sort="Redinski, John" uniqKey="Redinski J" first="John" last="Redinski">John Redinski</name></author><author><name sortKey="Ahmed, Seema" sort="Ahmed, Seema" uniqKey="Ahmed S" first="Seema" last="Ahmed">Seema Ahmed</name></author><author><name sortKey="Bernett, Jorge" sort="Bernett, Jorge" uniqKey="Bernett J" first="Jorge" last="Bernett">Jorge Bernett</name></author><author><name sortKey="Chelliah, Daniel" sort="Chelliah, Daniel" uniqKey="Chelliah D" first="Daniel" last="Chelliah">Daniel Chelliah</name></author><author><name sortKey="Chen, Danny" sort="Chen, Danny" uniqKey="Chen D" first="Danny" last="Chen">Danny Chen</name></author><author><name sortKey="Chihara, Shingo" sort="Chihara, Shingo" uniqKey="Chihara S" first="Shingo" last="Chihara">Shingo Chihara</name></author><author><name sortKey="Cohen, Stuart H" sort="Cohen, Stuart H" uniqKey="Cohen S" first="Stuart H." last="Cohen">Stuart H. Cohen</name></author><author><name sortKey="Cunningham, Jennifer" sort="Cunningham, Jennifer" uniqKey="Cunningham J" first="Jennifer" last="Cunningham">Jennifer Cunningham</name></author><author><name sortKey="D Rminio Monforte, Antonella" sort="D Rminio Monforte, Antonella" uniqKey="D Rminio Monforte A" first="Antonella" last="D Rminio Monforte">Antonella D Rminio Monforte</name></author><author><name sortKey="Ismail, Saad" sort="Ismail, Saad" uniqKey="Ismail S" first="Saad" last="Ismail">Saad Ismail</name></author><author><name sortKey="Kato, Hideaki" sort="Kato, Hideaki" uniqKey="Kato H" first="Hideaki" last="Kato">Hideaki Kato</name></author><author><name sortKey="Lapadula, Giuseppe" sort="Lapadula, Giuseppe" uniqKey="Lapadula G" first="Giuseppe" last="Lapadula">Giuseppe Lapadula</name></author><author><name sortKey="L Er, Erwan" sort="L Er, Erwan" uniqKey="L Er E" first="Erwan" last="L Er">Erwan L Er</name></author><author><name sortKey="Maeno, Toshitaka" sort="Maeno, Toshitaka" uniqKey="Maeno T" first="Toshitaka" last="Maeno">Toshitaka Maeno</name></author><author><name sortKey="Majumder, Sumit" sort="Majumder, Sumit" uniqKey="Majumder S" first="Sumit" last="Majumder">Sumit Majumder</name></author><author><name sortKey="Massari, Marco" sort="Massari, Marco" uniqKey="Massari M" first="Marco" last="Massari">Marco Massari</name></author><author><name sortKey="Mora Rillo, Marta" sort="Mora Rillo, Marta" uniqKey="Mora Rillo M" first="Marta" last="Mora-Rillo">Marta Mora-Rillo</name></author><author><name sortKey="Mutoh, Yoshikazu" sort="Mutoh, Yoshikazu" uniqKey="Mutoh Y" first="Yoshikazu" last="Mutoh">Yoshikazu Mutoh</name></author><author><name sortKey="Nguyen, Duc" sort="Nguyen, Duc" uniqKey="Nguyen D" first="Duc" last="Nguyen">Duc Nguyen</name></author><author><name sortKey="Verweij, Ewa" sort="Verweij, Ewa" uniqKey="Verweij E" first="Ewa" last="Verweij">Ewa Verweij</name></author><author><name sortKey="Zoufaly, Alexander" sort="Zoufaly, Alexander" uniqKey="Zoufaly A" first="Alexander" last="Zoufaly">Alexander Zoufaly</name></author><author><name sortKey="Osinusi, Anu O" sort="Osinusi, Anu O" uniqKey="Osinusi A" first="Anu O." last="Osinusi">Anu O. Osinusi</name></author><author><name sortKey="Dezure, Adam" sort="Dezure, Adam" uniqKey="Dezure A" first="Adam" last="Dezure">Adam Dezure</name></author><author><name sortKey="Zhao, Yang" sort="Zhao, Yang" uniqKey="Zhao Y" first="Yang" last="Zhao">Yang Zhao</name></author><author><name sortKey="Zhong, Lijie" sort="Zhong, Lijie" uniqKey="Zhong L" first="Lijie" last="Zhong">Lijie Zhong</name></author><author><name sortKey="Chokkalingam, Anand" sort="Chokkalingam, Anand" uniqKey="Chokkalingam A" first="Anand" last="Chokkalingam">Anand Chokkalingam</name></author><author><name sortKey="Elboudwarej, Emon" sort="Elboudwarej, Emon" uniqKey="Elboudwarej E" first="Emon" last="Elboudwarej">Emon Elboudwarej</name></author><author><name sortKey="Telep, Laura" sort="Telep, Laura" uniqKey="Telep L" first="Laura" last="Telep">Laura Telep</name></author><author><name sortKey="Timbs, Leighann" sort="Timbs, Leighann" uniqKey="Timbs L" first="Leighann" last="Timbs">Leighann Timbs</name></author><author><name sortKey="Henne, Ilana" sort="Henne, Ilana" uniqKey="Henne I" first="Ilana" last="Henne">Ilana Henne</name></author><author><name sortKey="Sellers, Scott" sort="Sellers, Scott" uniqKey="Sellers S" first="Scott" last="Sellers">Scott Sellers</name></author><author><name sortKey="Cao, Huyen" sort="Cao, Huyen" uniqKey="Cao H" first="Huyen" last="Cao">Huyen Cao</name></author><author><name sortKey="Tan, Susanna K" sort="Tan, Susanna K" uniqKey="Tan S" first="Susanna K." last="Tan">Susanna K. Tan</name></author><author><name sortKey="Winterbourne, Lucinda" sort="Winterbourne, Lucinda" uniqKey="Winterbourne L" first="Lucinda" last="Winterbourne">Lucinda Winterbourne</name></author><author><name sortKey="Desai, Polly" sort="Desai, Polly" uniqKey="Desai P" first="Polly" last="Desai">Polly Desai</name></author><author><name sortKey="Mera, Robertino" sort="Mera, Robertino" uniqKey="Mera R" first="Robertino" last="Mera">Robertino Mera</name></author><author><name sortKey="Gaggar, Anuj" sort="Gaggar, Anuj" uniqKey="Gaggar A" first="Anuj" last="Gaggar">Anuj Gaggar</name></author><author><name sortKey="Myers, Robert P" sort="Myers, Robert P" uniqKey="Myers R" first="Robert P." last="Myers">Robert P. Myers</name></author><author><name sortKey="Brainard, Diana M" sort="Brainard, Diana M" uniqKey="Brainard D" first="Diana M." last="Brainard">Diana M. Brainard</name></author><author><name sortKey="Childs, Richard" sort="Childs, Richard" uniqKey="Childs R" first="Richard" last="Childs">Richard Childs</name></author><author><name sortKey="Flanigan, Timothy" sort="Flanigan, Timothy" uniqKey="Flanigan T" first="Timothy" last="Flanigan">Timothy Flanigan</name></author></analytic><series><title level="j">The New England Journal of Medicine</title><idno type="ISSN">0028-4793</idno><idno type="eISSN">1533-4406</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><sec id="sc_a1"><title>Background</title><p>Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.</p></sec><sec id="sc_a2"><title>Methods</title><p>We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day.</p></sec><sec id="sc_a3"><title>Results</title><p>Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.</p></sec><sec id="sc_a4"><title>Conclusions</title><p>In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">N Engl J Med</journal-id><journal-id journal-id-type="iso-abbrev">N. Engl. J. Med</journal-id><journal-id journal-id-type="publisher-id">nejm</journal-id><journal-title-group><journal-title>The New England Journal of Medicine</journal-title></journal-title-group><issn pub-type="ppub">0028-4793</issn><issn pub-type="epub">1533-4406</issn><publisher><publisher-name>Massachusetts Medical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">7169476</article-id><article-id pub-id-type="doi">10.1056/NEJMoa2007016</article-id><article-id pub-id-type="publisher-id">NJ202004103820001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Compassionate Use of Remdesivir for Patients with Severe Covid-19</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grein</surname><given-names>Jonathan</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Ohmagari</surname><given-names>Norio</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>Daniel</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Diaz</surname><given-names>George</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Asperges</surname><given-names>Erika</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Castagna</surname><given-names>Antonella</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Feldt</surname><given-names>Torsten</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Green</surname><given-names>Gary</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Green</surname><given-names>Margaret L.</given-names></name><degrees>M.D., M.P.H.</degrees></contrib><contrib contrib-type="author"><name><surname>Lescure</surname><given-names>François-Xavier</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" specific-use="authenticated" authenticated="false">http://orcid.org/0000-0002-5606-8712</contrib-id><name><surname>Nicastri</surname><given-names>Emanuele</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" specific-use="authenticated" authenticated="false">http://orcid.org/0000-0002-6066-2853</contrib-id><name><surname>Oda</surname><given-names>Rentaro</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Yo</surname><given-names>Kikuo</given-names></name><degrees>M.D., D.M.Sc.</degrees></contrib><contrib contrib-type="author"><name><surname>Quiros-Roldan</surname><given-names>Eugenia</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Studemeister</surname><given-names>Alex</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Redinski</surname><given-names>John</given-names></name><degrees>D.O.</degrees></contrib><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Seema</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Bernett</surname><given-names>Jorge</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Chelliah</surname><given-names>Daniel</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Danny</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Chihara</surname><given-names>Shingo</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Cohen</surname><given-names>Stuart H.</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Cunningham</surname><given-names>Jennifer</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>D’Arminio Monforte</surname><given-names>Antonella</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Ismail</surname><given-names>Saad</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Kato</surname><given-names>Hideaki</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Lapadula</surname><given-names>Giuseppe</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>L’Her</surname><given-names>Erwan</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Maeno</surname><given-names>Toshitaka</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Majumder</surname><given-names>Sumit</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Massari</surname><given-names>Marco</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Mora-Rillo</surname><given-names>Marta</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Mutoh</surname><given-names>Yoshikazu</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Duc</given-names></name><degrees>M.D., Pharm.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Verweij</surname><given-names>Ewa</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Zoufaly</surname><given-names>Alexander</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Osinusi</surname><given-names>Anu O.</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>DeZure</surname><given-names>Adam</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yang</given-names></name><degrees>Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Lijie</given-names></name><degrees>Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Chokkalingam</surname><given-names>Anand</given-names></name><degrees>Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Elboudwarej</surname><given-names>Emon</given-names></name><degrees>Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Telep</surname><given-names>Laura</given-names></name><degrees>M.P.H.</degrees></contrib><contrib contrib-type="author"><name><surname>Timbs</surname><given-names>Leighann</given-names></name><degrees>B.A.</degrees></contrib><contrib contrib-type="author"><name><surname>Henne</surname><given-names>Ilana</given-names></name><degrees>M.S.</degrees></contrib><contrib contrib-type="author"><name><surname>Sellers</surname><given-names>Scott</given-names></name><degrees>Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Huyen</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Susanna K.</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Winterbourne</surname><given-names>Lucinda</given-names></name><degrees>B.A.</degrees></contrib><contrib contrib-type="author"><name><surname>Desai</surname><given-names>Polly</given-names></name><degrees>M.P.H.</degrees></contrib><contrib contrib-type="author"><name><surname>Mera</surname><given-names>Robertino</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Gaggar</surname><given-names>Anuj</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Myers</surname><given-names>Robert P.</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Brainard</surname><given-names>Diana M.</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Childs</surname><given-names>Richard</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Flanigan</surname><given-names>Timothy</given-names></name><degrees>M.D.</degrees></contrib><aff>From Cedars–Sinai Medical Center, Los Angeles (J.G.), El Camino Hospital, Mountain View (D.S., D. Chelliah), Sutter Santa Rosa Regional Hospital, Santa Rosa (G.G.), Regional Medical Center (A.S., J.R.) and Good Samaritan Hospital (S.M.), San Jose, John Muir Health, Walnut Creek (J.B.), UC Davis Health, Sacramento (S.H.C.), NorthBay Medical Center, Fairfield (S.I.), and Gilead Sciences, Foster City (A.O.O., A.D., Y.Z., L.Z., A. Chokkalingam, E.E., L. Telep, L. Timbs, I.H., S.S., H.C., S.K.T., L.W., P.D., R.M., A.G., R.P.M., D.M.B.) — all in California; the National Center for Global Health and Medicine, Tokyo (N.O.), Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu City (R.O.), Hiratsuka City Hospital, Hiratsuka (K.Y.), Yokohama City University Hospital, Yokohama (H.K.), Gunma University Hospital, Gunma (T.M.), and Tosei General Hospital, Seto (Y.M.) — all in Japan; Providence Regional Medical Center Everett, Everett (G.D.), and University of Washington Medical Center–Northwest (M.L.G.) and Virginia Mason Medical Center (S. Chihara), Seattle — all in Washington; Fondazione IRCCS Policlinico San Matteo, Pavia (E.A.), IRCCS, San Raffaele Scientific Institute (A. Castagna) and Azienda Socio Sanitaria Territoriale Spedali (ASST) Santi Paolo e Carlo, Department of Health Services, University of Milan (A.D.M.), Milan, National Institute for Infectious Diseases, IRCCS, L. Spallanzani, Rome (E.N.), Università degli Study of Brescia, ASST Civili di Brescia, Brescia (E.Q.-R.), San Gerardo Hospital, ASST Monza, University of Milan–Bicocca, Monza (G.L.), and Azienda Unite Sanitarie Locali–IRCCS, Reggio Emilia (M.M.) — all in Italy; Universitätsklinikum Düsseldorf, Düsseldorf, Germany (T. Feldt); Université de Paris, Infection, Antimicrobiens, Modélisation, Evolution (IAME), INSERM, and Assistance Publique–Hôpitaux de Paris, Department of Infectious Diseases, Bichat Hospital, Paris (F.-X.L.), Centre Hospitalier Régional et Universitaire de Brest–La Cavale Blanche, Brest (E.L.), and Division of Infectious Diseases and Tropical Medicine, University Hospital of Bordeaux, Bordeaux (D.N.) — all in France; St. Alexius Medical Center, Hoffman Estates, IL (S.A.); Mackenzie Health, Richmond Hill, ON, Canada (D. Chen); Columbia University Irving Medical Center, New York (J.C.); Hospital Universitario La Paz–Carlos III, Instituto de Investigación Hospital Universitario La Paz, Madrid (M.M.-R.); Bernhoven Hospital, Uden, the Netherlands (E.V.); Kaiser Franz Josef Hospital, Vienna (A.Z.); the U.S. Public Health Service Commissioned Corps, Washington, DC (R.C.); and Miriam Hospital, Providence, RI (T. Flanigan).</aff></contrib-group><author-notes><corresp>Address reprint requests to Dr. Brainard at Gilead Sciences, 333 Lakeside Dr., Foster City, CA 94404, or at <email xlink:href="diana.brainard@gilead.com">diana.brainard@gilead.com</email>.</corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>4</month><year>2020</year></pub-date><elocation-id>NEJMoa2007016</elocation-id><permissions><copyright-statement>Copyright © 2020 Massachusetts Medical Society. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Massachusetts Medical Society</copyright-holder><license specific-use="PMC_Covid-19"><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the Covid-19 pandemic or until revoked in writing. Upon expiration of these permissions, PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="NEJMoa2007016.pdf"></self-uri><abstract abstract-type="summary"><title>Abstract</title><sec id="sc_a1"><title>Background</title><p>Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.</p></sec><sec id="sc_a2"><title>Methods</title><p>We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day.</p></sec><sec id="sc_a3"><title>Results</title><p>Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.</p></sec><sec id="sc_a4"><title>Conclusions</title><p>In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)</p></sec></abstract><kwd-group kwd-group-type="nejm-topics"><nested-kwd><compound-kwd><compound-kwd-part content-type="code">12</compound-kwd-part><compound-kwd-part content-type="keyword">Pulmonary/Critical Care</compound-kwd-part></compound-kwd><nested-kwd><compound-kwd><compound-kwd-part content-type="code">12_1</compound-kwd-part><compound-kwd-part content-type="keyword">Pulmonary/Critical Care General</compound-kwd-part></compound-kwd></nested-kwd></nested-kwd><nested-kwd><compound-kwd><compound-kwd-part content-type="code">18</compound-kwd-part><compound-kwd-part content-type="keyword">Infectious Disease</compound-kwd-part></compound-kwd><nested-kwd><compound-kwd><compound-kwd-part content-type="code">18_1</compound-kwd-part><compound-kwd-part content-type="keyword">Infectious Disease General</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="code">18_6</compound-kwd-part><compound-kwd-part content-type="keyword">Viral Infections</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="code">18_9</compound-kwd-part><compound-kwd-part content-type="keyword">Global Health</compound-kwd-part></compound-kwd></nested-kwd></nested-kwd></kwd-group><custom-meta-group><custom-meta><meta-name>release-date-display-string</meta-name><meta-value>2020-04-10T15:00:00-04:00</meta-value></custom-meta><custom-meta><meta-name>release-date-year</meta-name><meta-value>2020</meta-value></custom-meta><custom-meta><meta-name>release-date-month</meta-name><meta-value>04</meta-value></custom-meta><custom-meta><meta-name>release-date-day</meta-name><meta-value>10</meta-value></custom-meta><custom-meta><meta-name>release-date-hour</meta-name><meta-value>15</meta-value></custom-meta><custom-meta><meta-name>release-date-minute</meta-name><meta-value>00</meta-value></custom-meta><custom-meta><meta-name>release-date-second</meta-name><meta-value>00</meta-value></custom-meta><custom-meta><meta-name>release-date-time-zone</meta-name><meta-value>-04:00</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Since the first cases were reported in December 2019, infection with the severe acute respiratory coronavirus 2 (SARS-CoV-2) has become a worldwide pandemic.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref></sup> Covid-19 — the illness caused by SARS-CoV-2 — is overwhelming health care systems globally.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref></sup> The symptoms of SARS-CoV-2 infection vary widely, from asymptomatic disease to pneumonia and life-threatening complications, including acute respiratory distress syndrome, multisystem organ failure, and ultimately, death.<sup><xref rid="r5" ref-type="bibr">5-7</xref></sup> Older patients and those with preexisting respiratory or cardiovascular conditions appear to be at the greatest risk for severe complications.<sup><xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup> In the absence of a proven effective therapy, current management consists of supportive care, including invasive and noninvasive oxygen support and treatment with antibiotics.<sup><xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref></sup> In addition, many patients have received off-label or compassionate-use therapies, including antiretrovirals, antiparasitic agents, antiinflammatory compounds, and convalescent plasma.<sup><xref rid="r10" ref-type="bibr">10-13</xref></sup></p><p>Remdesivir is a prodrug of a nucleotide analogue that is intracellularly metabolized to an analogue of adenosine triphosphate that inhibits viral RNA polymerases. Remdesivir has broad-spectrum activity against members of several virus families, including filoviruses (e.g., Ebola) and coronaviruses (e.g., SARS-CoV and Middle East respiratory syndrome coronavirus [MERS-CoV]) and has shown prophylactic and therapeutic efficacy in nonclinical models of these coronaviruses.<sup><xref rid="r14" ref-type="bibr">14-17</xref></sup> In vitro testing has also shown that remdesivir has activity against SARS-CoV-2. Remdesivir appears to have a favorable clinical safety profile, as reported on the basis of experience in approximately 500 persons, including healthy volunteers and patients treated for acute Ebola virus infection,<sup><xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref></sup> and supported by our data (on file and shared with the World Health Organization [WHO]). In this report, we describe outcomes in a cohort of patients hospitalized for severe Covid-19 who were treated with remdesivir on a compassionate-use basis.</p><sec sec-type="methods" id="sc1"><title>Methods</title><sec id="sc1.1"><title>Patients</title><p>Gilead Sciences began accepting requests from clinicians for compassionate use of remdesivir on January 25, 2020. To submit a request, clinicians completed an assessment form with demographic and disease-status information about their patient (see the <xref ref-type="app" rid="ap2">Supplementary Appendix</xref>, available with the full text of this article at NEJM.org). Approval of requests was reserved for hospitalized patients who had SARS-CoV-2 infection confirmed by reverse-transcriptase–polymerase-chain-reaction assay and either an oxygen saturation of 94% or less while the patient was breathing ambient air or a need for oxygen support. In addition, patients were required to have a creatinine clearance above 30 ml per minute and serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than five times the upper limit of the normal range, and they had to agree not to use other investigational agents for Covid-19.</p><p>In approved cases, the planned treatment was a 10-day course of remdesivir, consisting of a loading dose of 200 mg intravenously on day 1, plus 100 mg daily for the following 9 days. Supportive therapy was to be provided at the discretion of the clinicians. Follow-up was to continue through at least 28 days after the beginning of treatment with remdesivir or until discharge or death. Data that were collected through March 30, 2020, are reported here. This open-label program did not have a predetermined number of patients, number of sites, or duration. Data for some patients included in this analysis have been reported previously.<sup><xref rid="r20" ref-type="bibr">20-22</xref></sup> Details of the study design and conduct can be seen in the <xref ref-type="app" rid="ap1">protocol</xref> (available at NEJM.org).</p></sec><sec id="sc1.2"><title>Study Assessments</title><p>Data on patients’ oxygen-support requirements, adverse events, and laboratory values, including serum creatinine, ALT, and AST, were to be reported daily, from day 1 through day 10, and additional follow-up information was solicited through day 28. Although there were no prespecified end points for this program, we quantified the incidence of key clinical events, including changes in oxygen-support requirements (ambient air, low-flow oxygen, nasal high-flow oxygen, noninvasive positive pressure ventilation [NIPPV], invasive mechanical ventilation, and extracorporeal membrane oxygenation [ECMO]), hospital discharge, and reported adverse events, including those leading to discontinuation of treatment, serious adverse events, and death. In addition, we evaluated the proportion of patients with clinical improvement, as defined by live discharge from the hospital, a decrease of at least 2 points from baseline on a modified ordinal scale (as recommended by the WHO R&D Blueprint Group), or both. The six-point scale consists of the following categories: 1, not hospitalized; 2, hospitalized, not requiring supplemental oxygen; 3, hospitalized, requiring supplemental oxygen; 4, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 5, hospitalized, requiring invasive mechanical ventilation, ECMO, or both; and 6, death.</p></sec><sec id="sc1.3"><title>Program Oversight</title><p>Regulatory and institutional review board or independent ethics committee approval was obtained for each patient treated with remdesivir, and consent was obtained for all patients in accordance with local regulations. The program was designed and conducted by the sponsor (Gilead Sciences), in accordance with the <xref ref-type="app" rid="ap1">protocol</xref>. The sponsor collected the data, monitored conduct of the program, and performed the statistical analyses. All authors had access to the data and assume responsibility for the integrity and completeness of the reported data. The initial draft of the manuscript was prepared by a writer employed by Gilead Sciences along with one of the authors, with input from all the authors.</p></sec><sec id="sc1.4"><title>Statistical Analysis</title><p>No sample-size calculations were performed. The analysis population included all patients who received their first dose of remdesivir on or before March 7, 2020, and for whom clinical data for at least 1 subsequent day were available. Clinical improvement and mortality in the remdesivir compassionate-use cohort were described with the use of Kaplan–Meier analysis. Associations between pretreatment characteristics and these outcomes were evaluated with Cox proportional hazards regression. Because the analysis did not include a provision for correcting for multiple comparisons in tests for association between baseline variables and outcomes, results are reported as point estimates and 95% confidence intervals. The widths of the confidence intervals have not been adjusted for multiple comparisons, so the intervals should not be used to infer definitive associations with outcomes. All analyses were conducted with SAS software, version 9.4 (SAS Institute).</p></sec></sec><sec sec-type="results" id="sc2"><title>Results</title><sec id="sc2.1"><title>Patients</title><p>In total, 61 patients received at least one dose of remdesivir on or before March 7, 2020; 8 of these patients were excluded because of missing postbaseline information (7 patients) and an erroneous remdesivir start date (1 patient) (Fig. S1 in the <xref ref-type="app" rid="ap2">Supplementary Appendix</xref>). Of the 53 remaining patients included in this analysis, 40 (75%) received the full 10-day course of remdesivir, 10 (19%) received 5 to 9 days of treatment, and 3 (6%) fewer than 5 days of treatment.</p></sec><sec id="sc2.2"><title>Baseline Characteristics of the Patients</title><p><xref rid="t1" ref-type="table">Table 1</xref> shows baseline demographic and clinical characteristics of the 53 patients in the compassionate-use cohort. Patients were enrolled in the United States (22 patients), Japan (9), Italy (12), Austria (1), France (4), Germany (2), Netherlands (1), Spain (1), and Canada (1). A total of 40 patients (75%) were men, the age range was 23 to 82 years, and the median age was 64 years (interquartile range, 48 to 71). At baseline, the majority of patients (34 [64%]) were receiving invasive ventilation, including 30 (57%) receiving mechanical ventilation and 4 (8%) receiving ECMO. The median duration of invasive mechanical ventilation before the initiation of remdesivir treatment was 2 days (interquartile range, 1 to 8). As compared with patients who were receiving noninvasive oxygen support at baseline, those receiving invasive ventilation tended to be older (median age, 67 years, vs. 53 years), were more likely to be male (79%, vs. 68%), had higher median serum ALT (48 U per liter, vs. 27) and creatinine (0.90 mg per deciliter, vs. 0.79 [79.6 μmol per liter, vs. 69.8]), and a higher prevalence of coexisting conditions, including hypertension (26%, vs. 21%), diabetes (24%, vs. 5%), hyperlipidemia (18%, vs. 0%), and asthma (15%, vs. 5%). The median duration of symptoms before the initiation of remdesivir treatment was 12 days (interquartile range, 9 to 15) and did not differ substantially between patients receiving invasive ventilation and those receiving noninvasive ventilation (<xref rid="t1" ref-type="table">Table 1</xref>).</p></sec><sec id="sc2.3"><title>Clinical Improvement during Remdesivir Treatment</title><p>Over a median follow-up of 18 days (interquartile range, 13 to 23) after receiving the first dose of remdesivir, 36 of 53 patients (68%) showed an improvement in the category of oxygen support, whereas 8 of 53 patients (15%) showed worsening (<xref ref-type="fig" rid="f1">Figure 1</xref>). Improvement was observed in all 12 patients who were breathing ambient air or receiving low-flow supplemental oxygen and in 5 of 7 patients (71%) who were receiving noninvasive oxygen support (NIPPV or high-flow supplemental oxygen). It is notable that 17 of 30 patients (57%) who were receiving invasive mechanical ventilation were extubated, and 3 of 4 patients (75%) receiving ECMO stopped receiving it; all were alive at last follow-up. Individual patients’ changes in the category of oxygen support are shown in <xref ref-type="fig" rid="f2">Figure 2</xref>. By the date of the most recent follow-up, 25 of 53 patients (47%) had been discharged (24% receiving invasive ventilation [8 of 34 patients] and 89% [17 of 19 patients] receiving noninvasive oxygen support).</p><p>By 28 days of follow-up, the cumulative incidence of clinical improvement, as defined by either a decrease of 2 points or more on the six-point ordinal scale or live discharge, was 84% (95% confidence interval [CI], 70 to 99) by Kaplan–Meier analysis (<xref ref-type="fig" rid="f3">Figure 3A</xref>). Clinical improvement was less frequent among patients receiving invasive ventilation than among those receiving noninvasive ventilation (hazard ratio for improvement, 0.33; 95% CI, 0.16 to 0.68) (<xref ref-type="fig" rid="f3">Figure 3B</xref>) and among patients 70 years of age or older (hazard ratio as compared with patients younger than 50 years, 0.29; 95% CI, 0.11 to 0.74) (<xref ref-type="fig" rid="f3">Figure 3C</xref>). Sex, region of enrollment, coexisting conditions, and duration of symptoms before remdesivir treatment was initiated were not significantly associated with clinical improvement (Table S1).</p></sec><sec id="sc2.4"><title>Mortality</title><p>Seven of the 53 patients (13%) died after the completion of remdesivir treatment, including 6 of 34 patients (18%) who were receiving invasive ventilation and 1 of 19 (5%) who were receiving noninvasive oxygen support (see the <xref ref-type="app" rid="ap2">Supplementary Appendix</xref> for case narratives). The median interval between remdesivir initiation and death was 15 days (interquartile range, 9 to 17). Overall mortality from the date of admission was 0.56 per 100 hospitalization days (95% CI, 0.14 to 0.97) and did not differ substantially among patients receiving invasive ventilation (0.57 per 100 hospitalization days; 95% CI, 0 to 1.2]) as compared with those receiving noninvasive ventilation (0.51 per 100 hospitalization days; 95% CI, 0.07 to 1.1]). Risk of death was greater among patients who were 70 years of age or older (hazard ratio as compared with patients younger than 70 years, 11.34; 95% CI, 1.36 to 94.17) and among those with higher serum creatinine at baseline (hazard ratio per milligram per deciliter, 1.91; 95% CI, 1.22 to 2.99). The hazard ratio for patients receiving invasive ventilation as compared with those receiving noninvasive oxygen support was 2.78 (95% CI, 0.33 to 23.19) (Table S2).</p></sec><sec id="sc2.5"><title>Safety</title><p>A total of 32 patients (60%) reported adverse events during follow-up (<xref rid="t2" ref-type="table">Table 2</xref>). The most common adverse events were increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension. In general, adverse events were more common in patients receiving invasive ventilation. A total of 12 patients (23%) had serious adverse events. The most common serious adverse events — multiple-organ-dysfunction syndrome, septic shock, acute kidney injury, and hypotension — were reported in patients who were receiving invasive ventilation at baseline.</p><p>Four patients (8%) discontinued remdesivir treatment prematurely: one because of worsening of preexisting renal failure, one because of multiple organ failure, and two because of elevated aminotransferases, including one patient with a maculopapular rash.</p></sec><sec id="sc2.6"><title>Laboratory Data</title><p>Given the nature of this compassionate-use program, data on a limited number of laboratory measures were collected. Median serum ALT, AST, and creatinine fluctuated during follow-up (Fig. S2).</p></sec></sec><sec sec-type="discussion" id="sc3"><title>Discussion</title><p>To date, no therapy has demonstrated efficacy for patients with Covid-19. This preliminary report describes the clinical outcomes in a small cohort of patients who were severely ill with Covid-19 and were treated with remdesivir. Although data from several ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for Covid-19, the outcomes observed in this compassionate-use program are the best currently available data. Specifically, improvement in oxygen-support status was observed in 68% of patients, and overall mortality was 13% over a median follow-up of 18 days. In a recent randomized, controlled trial of lopinavir–ritonavir in patients hospitalized for Covid-19, the 28-day mortality was 22%.<sup><xref rid="r10" ref-type="bibr">10</xref></sup> It is important to note that only 1 of 199 patients in that trial were receiving invasive ventilation at baseline. In case series and cohort studies, largely from China, mortality rates of 17 to 78% have been reported in severe cases, defined by the need for admission to an intensive care unit, invasive ventilation, or both.<sup><xref rid="r23" ref-type="bibr">23-28</xref></sup> For example, among 201 patients hospitalized in Wuhan, China, mortality was 22% overall and 66% (44 of 67) among patients receiving invasive mechanical ventilation.<sup><xref rid="r7" ref-type="bibr">7</xref></sup> By way of comparison, the 13% mortality observed in this remdesivir compassionate-use cohort is noteworthy, considering the severity of disease in this patient population; however, the patients enrolled in this compassionate-treatment program are not directly comparable to those studied in these other reports. For example, 64% of remdesivir-treated patients were receiving invasive ventilation at baseline, including 8% who were receiving ECMO, and mortality in this subgroup was 18% (as compared with 5.3% in patients receiving noninvasive oxygen support), and the majority (75%) of patients were male, were over 60 years of age, and had coexisting conditions.</p><p>Unfortunately, our compassionate-use program did not collect viral load data to confirm the antiviral effects of remdesivir or any association between baseline viral load and viral suppression, if any, and clinical response. Moreover, the duration of remdesivir therapy was not entirely uniform in our study, largely because clinical improvement enabled discharge from the hospital. The effectiveness of a shorter duration of therapy (e.g., 5 days, as compared with 10 days), which would allow the treatment of more patients during the pandemic, is being assessed in ongoing randomized trials of this therapy.</p><p>No new safety signals were detected during short-term remdesivir therapy in this compassionate-use cohort. Nonclinical toxicology studies have shown renal abnormalities, but no clear evidence of nephrotoxicity due to remdesivir therapy was observed. As reported in studies in healthy volunteers and patients infected with Ebola virus, mild-to-moderate elevations in ALT, AST, or both were observed in this cohort of patients with severe Covid-19.<sup><xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref></sup> However, considering the frequency of liver dysfunction in patients with Covid-19, attribution of hepatotoxicity to either remdesivir or the underlying disease is challenging.<sup><xref rid="r29" ref-type="bibr">29</xref></sup> Nevertheless, the safety and side-effect profile of remdesivir in patients with Covid-19 require proper assessment in placebo-controlled trials.</p><p>Interpretation of the results of this study is limited by the small size of the cohort, the relatively short duration of follow-up, potential missing data owing to the nature of the program, the lack of information on 8 of the patients initially treated, and the lack of a randomized control group. Although the latter precludes definitive conclusions, comparisons with contemporaneous cohorts from the literature, in whom general care is expected to be consistent with that of our cohort, suggest that remdesivir may have clinical benefit in patients with severe Covid-19. Nevertheless, other factors may have contributed to differences in outcomes, including the type of supportive care (e.g., concomitant medications or variations in ventilatory practices) and differences in institutional treatment protocols and thresholds for hospitalization. Moreover, the use of invasive ventilation as a proxy for disease severity may be influenced by the availability of ventilators in a given location. The findings from these uncontrolled data will be informed by the ongoing randomized, placebo-controlled trials of remdesivir therapy for Covid-19.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>Supported by Gilead Sciences.</p></fn><fn fn-type="financial-disclosure"><p><xref ref-type="app" rid="ap3">Disclosure forms</xref> provided by the authors are available with the full text of this article at NEJM.org.</p></fn></fn-group><ack><p>We thank Sarah Tse, Deborah Ajayi, and Gretchen Schmelz of BioScience Communications for creating earlier versions of the figures. Writing and editorial assistance with earlier versions of the manuscript were provided by David McNeel and Sandra Chen, both of Gilead Sciences. The names of those who assisted in the care of the patients in this program are listed in the <xref ref-type="app" rid="ap2">Supplementary Appendix</xref>. We express our solidarity with those who are or have been ill with Covid-19, their families, and the health care workers on the front lines of this pandemic.</p></ack><notes><p content-type="published/updated">This article was published on April 10, 2020, at NEJM.org.</p></notes><app-group><app content-type="protocol" id="ap1"><title>Protocol</title><supplementary-material content-type="local-data"><media xlink:href="NEJMoa2007016_protocol.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app><app content-type="supplementary-appendix" id="ap2"><title>Supplementary Appendix</title><supplementary-material content-type="local-data"><media xlink:href="NEJMoa2007016_appendix.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app><app content-type="disclosures" id="ap3"><title>Disclosure Forms</title><supplementary-material content-type="local-data"><media xlink:href="NEJMoa2007016_disclosures.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Cucinotta</surname><given-names>D</given-names></string-name>, <string-name><surname>Vanelli</surname><given-names>M</given-names></string-name>. <article-title>WHO declares COVID-19 a pandemic.</article-title><source>Acta Biomed</source><year>2020</year>;<volume>91</volume>:<fpage>157</fpage>-<lpage>160</lpage>.<pub-id pub-id-type="pmid">32191675</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Spinelli</surname><given-names>A</given-names></string-name>, <string-name><surname>Pellino</surname><given-names>G</given-names></string-name>. <article-title>COVID-19 pandemic: perspectives on an unfolding crisis.</article-title><source>Br J Surg</source><year>2020</year><month>3</month><day>19</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32191340</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Fauci</surname><given-names>AS</given-names></string-name>, <string-name><surname>Lane</surname><given-names>HC</given-names></string-name>, <string-name><surname>Redfield</surname><given-names>RR</given-names></string-name>. <article-title>Covid-19 — navigating the uncharted.</article-title><source>N Engl J Med</source><year>2020</year>;<volume>382</volume>:<fpage>1268</fpage>-<lpage>1269</lpage>.<pub-id pub-id-type="pmid">32109011</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Mahase</surname><given-names>E</given-names></string-name>, <string-name><surname>Kmietowicz</surname><given-names>Z</given-names></string-name>. <article-title>Covid-19: doctors are told not to perform CPR on patients in cardiac arrest.</article-title><source>BMJ</source><year>2020</year>;<volume>368</volume>:<fpage>m1282</fpage>-<lpage>m1282</lpage>.<pub-id pub-id-type="pmid">32224494</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Rodriguez-Morales</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Cardona-Ospina</surname><given-names>JA</given-names></string-name>, <string-name><surname>Gutiérrez-Ocampo</surname><given-names>E</given-names></string-name>, <etal>et al.</etal><article-title>Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis.</article-title><source>Travel Med Infect Dis</source><year>2020</year><month>3</month><day>13</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32179124</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Weiss</surname><given-names>P</given-names></string-name>, <string-name><surname>Murdoch</surname><given-names>DR</given-names></string-name>. <article-title>Clinical course and mortality risk of severe COVID-19.</article-title><source>Lancet</source><year>2020</year>;<volume>395</volume>:<fpage>1014</fpage>-<lpage>1015</lpage>.<pub-id pub-id-type="pmid">32197108</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name><surname>Cai</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal><article-title>Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.</article-title><source>JAMA Intern Med</source><year>2020</year><month>3</month><day>13</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32167524</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Onder</surname><given-names>G</given-names></string-name>, <string-name><surname>Rezza</surname><given-names>G</given-names></string-name>, <string-name><surname>Brusaferro</surname><given-names>S</given-names></string-name>. <article-title>Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy.</article-title><source>JAMA</source><year>2020</year><month>3</month><day>23</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32203977</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Poston</surname><given-names>JT</given-names></string-name>, <string-name><surname>Patel</surname><given-names>BK</given-names></string-name>, <string-name><surname>Davis</surname><given-names>AM</given-names></string-name>. <article-title>Management of critically ill adults with COVID-19.</article-title><source>JAMA</source><year>2020</year><month>3</month><day>26</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32215647</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Cao</surname><given-names>B</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wen</surname><given-names>D</given-names></string-name>, <etal>et al.</etal><article-title>A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19.</article-title><source>N Engl J Med</source>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id>.</mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>F</given-names></string-name>, <etal>et al.</etal><article-title>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma.</article-title><source>JAMA</source><year>2020</year><month>3</month><day>27</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32219428</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Touret</surname><given-names>F</given-names></string-name>, <string-name><surname>de Lamballerie</surname><given-names>X</given-names></string-name>. <article-title>Of chloroquine and COVID-19.</article-title><source>Antiviral Res</source><year>2020</year><month>3</month><day>5</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32147496</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Baden</surname><given-names>LR</given-names></string-name>, <string-name><surname>Rubin</surname><given-names>EJ</given-names></string-name>. <article-title>Covid-19 — the search for effective therapy.</article-title><source>N Engl J Med</source>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMe2005477</pub-id>.</mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>de Wit</surname><given-names>E</given-names></string-name>, <string-name><surname>Feldmann</surname><given-names>F</given-names></string-name>, <string-name><surname>Cronin</surname><given-names>J</given-names></string-name>, <etal>et al.</etal><article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year>;<volume>117</volume>:<fpage>6771</fpage>-<lpage>6776</lpage>.<pub-id pub-id-type="pmid">32054787</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Sheahan</surname><given-names>TP</given-names></string-name>, <string-name><surname>Sims</surname><given-names>AC</given-names></string-name>, <string-name><surname>Graham</surname><given-names>RL</given-names></string-name>, <etal>et al.</etal><article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.</article-title><source>Sci Transl Med</source><year>2017</year>;<volume>9</volume>(<issue>396</issue>):<fpage>eaal3653</fpage>-<lpage>eaal3653</lpage>.<pub-id pub-id-type="pmid">28659436</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Sheahan</surname><given-names>TP</given-names></string-name>, <string-name><surname>Sims</surname><given-names>AC</given-names></string-name>, <string-name><surname>Leist</surname><given-names>SR</given-names></string-name>, <etal>et al.</etal><article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.</article-title><source>Nat Commun</source><year>2020</year>;<volume>11</volume>:<fpage>222</fpage>-<lpage>222</lpage>.<pub-id pub-id-type="pmid">31924756</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Cao</surname><given-names>R</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.</article-title><source>Cell Res</source><year>2020</year>;<volume>30</volume>:<fpage>269</fpage>-<lpage>271</lpage>.<pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Mulangu</surname><given-names>S</given-names></string-name>, <string-name><surname>Dodd</surname><given-names>LE</given-names></string-name>, <string-name><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></string-name>, <etal>et al.</etal><article-title>A randomized, controlled trial of Ebola virus disease therapeutics.</article-title><source>N Engl J Med</source><year>2019</year>;<volume>381</volume>:<fpage>2293</fpage>-<lpage>2303</lpage>.<pub-id pub-id-type="pmid">31774950</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="eref"><collab>European Medicines Agency</collab>. Summary on compassionate use: Remdesivir Gilead. April 3, <year>2020</year> (<uri xlink:href="https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf">https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf</uri>).</mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="eref"><string-name><surname>Kujawski</surname><given-names>SA</given-names></string-name>, <string-name><surname>Wong</surname><given-names>KK</given-names></string-name>, <string-name><surname>Collins</surname><given-names>JP</given-names></string-name>, <etal>et al.</etal><article-title>First 12 patients with coronavirus disease 2019 (COVID-19) in the United States.</article-title><source>medRxiv</source>, <month>3</month><day>12</day>, <year>2020</year> (<uri xlink:href="https://www.medrxiv.org/content/10.1101/2020.03.09.20032896v1">https://www.medrxiv.org/content/10.1101/2020.03.09.20032896v1</uri>).</mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Holshue</surname><given-names>ML</given-names></string-name>, <string-name><surname>DeBolt</surname><given-names>C</given-names></string-name>, <string-name><surname>Lindquist</surname><given-names>S</given-names></string-name>, <etal>et al.</etal><article-title>First case of 2019 novel coronavirus in the United States.</article-title><source>N Engl J Med</source><year>2020</year>;<volume>382</volume>:<fpage>929</fpage>-<lpage>936</lpage>.<pub-id pub-id-type="pmid">32004427</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Lescure</surname><given-names>FX</given-names></string-name>, <string-name><surname>Bouadma</surname><given-names>L</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>D</given-names></string-name>, <etal>et al.</etal><article-title>Clinical and virological data of the first cases of COVID-19 in Europe: a case series.</article-title><source>Lancet Infect Dis</source><year>2020</year><month>3</month><day>27</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32224310</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Arentz</surname><given-names>M</given-names></string-name>, <string-name><surname>Yim</surname><given-names>E</given-names></string-name>, <string-name><surname>Klaff</surname><given-names>L</given-names></string-name>, <etal>et al.</etal><article-title>Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State.</article-title><source>JAMA</source><year>2020</year><month>3</month><day>19</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32191259</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name><surname>Hu</surname><given-names>B</given-names></string-name>, <string-name><surname>Hu</surname><given-names>C</given-names></string-name>, <etal>et al.</etal><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.</article-title><source>JAMA</source><year>2020</year><month>2</month><day>7</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32031570</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name><surname>McGoogan</surname><given-names>JM</given-names></string-name>. <article-title>Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.</article-title><source>JAMA</source><year>2020</year><month>2</month><day>24</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32091533</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname><given-names>F</given-names></string-name>, <string-name><surname>Yu</surname><given-names>T</given-names></string-name>, <string-name><surname>Du</surname><given-names>R</given-names></string-name>, <etal>et al.</etal><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.</article-title><source>Lancet</source><year>2020</year>;<volume>395</volume>:<fpage>1054</fpage>-<lpage>1062</lpage>.<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Bhatraju</surname><given-names>PK</given-names></string-name>, <string-name><surname>Ghassemieh</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Nichols</surname><given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Covid-19 in critically ill patients in the Seattle region — case series.</article-title><source>N Engl J Med</source>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa2004500</pub-id>.</mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="eref">ICNARC report on COVID-19 in critical care. London: Intensive Care National Audit & Research Centre, March 27, <year>2020</year> (<uri xlink:href="https://www.icnarc.org/DataServices/Attachments/Download/b5f59585-5870-ea11-9124-00505601089b">https://www.icnarc.org/DataServices/Attachments/Download/b5f59585-5870-ea11-9124-00505601089b</uri>).</mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name><surname>Shi</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>FS</given-names></string-name>. <article-title>Liver injury in COVID-19: management and challenges.</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><month>3</month><day>4</day><comment>(Epub ahead of print)</comment>.<pub-id pub-id-type="pmid">32145190</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Oxygen-Support Status at Baseline and after Treatment.</title><p>For each oxygen-support category, percentages were calculated with the number of patients at baseline as the denominator. Improvement (blue cells), no change (beige) and worsening (gray) in oxygen-support status are shown. Invasive ventilation includes invasive mechanical ventilation, extracorporeal membrane oxygenation (ECMO), or both. Noninvasive ventilation includes nasal high-flow oxygen therapy, noninvasive positive pressure ventilation (NIPPV), or both.</p></caption><graphic xlink:href="NEJMoa2007016_f1"></graphic></fig><fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Changes in Oxygen-Support Status from Baseline in Individual Patients.</title><p>Baseline (day 0) was the day on which treatment with remdesivir (RDV) was initiated. Final oxygen support statuses shown are based on the most recent reported data. For each patient, the colors in the line represent the oxygen-support status of the patient over time. The colored circles to the left of each line indicate the patient’s overall change in status from baseline. A patient’s status “improved” if the oxygen-support status improved before the last follow-up or the patient was discharged. The vertical black marks show the last day of treatment with RDV. The gray dashed lines represent missing data between the patient’s most recent reported oxygen status and an event (death or discharge) or the last dose of RDV. A solid square at the end of a line indicates that the patient died; an open diamond indicates that the patient was discharged from the hospital. If there is neither a square nor a diamond at the end of a line, neither death nor discharge had occurred. Patient 2 was breathing ambient air through day 36. Patients 19 and 31 were discharged on day 44.</p></caption><graphic xlink:href="NEJMoa2007016_f2"></graphic></fig><fig id="f3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Cumulative Incidence of Clinical Improvement from Baseline to Day 36.</title><p>Clinical improvement is shown in the full cohort, in the cohort stratified according to ventilation status at baseline, and in the cohort stratified by age.</p></caption><graphic xlink:href="NEJMoa2007016_f3"></graphic></fig><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline Demographic and Clinical Characteristics of the Patients.<xref ref-type="table-fn" rid="t1fn1">*</xref></title></caption><alternatives><graphic xlink:href="NEJMoa2007016_t1"></graphic><table frame="hsides" rules="groups" content-type="tgroup"><colgroup span="1"><col id="t1col1" width="43.03%" span="1"></col><col id="t1col2" width="19.56%" span="1"></col><col id="t1col3" width="21.12%" span="1"></col><col id="t1col4" width="16.29%" span="1"></col></colgroup><thead content-type="thead sticky"><tr content-type="row head1"><th align="left" valign="bottom" content-type="entry txlx-borders" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="bottom" content-type="entry txxx-borders" rowspan="1" colspan="1">Invasive<break></break>Ventilation<break></break>(N=34)</th><th align="center" valign="bottom" content-type="entry txxx-borders" rowspan="1" colspan="1">Noninvasive<break></break>Oxygen Support<break></break>(N=19)</th><th align="center" valign="bottom" content-type="entry txxr-borders" rowspan="1" colspan="1">Total<break></break>(N=53)</th></tr></thead><tbody content-type="tbody"><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02 shading" rowspan="1" colspan="1">Median age (IQR) — yr</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">67 (56–72)</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">53 (41–68)</td><td align="center" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1">64 (48–71)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02" rowspan="1" colspan="1">Age category — no. (%)</td><td align="left" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"></td><td align="left" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"></td><td align="left" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1"></td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1"><50 yr</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">6 (18)</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">8 (42)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">14 (26)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">50 to <70 yr</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">14 (41)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">7 (37)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">21 (40)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">≥70 yr</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">14 (41)</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">4 (21)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">18 (34)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02" rowspan="1" colspan="1">Male sex — no. (%)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">27 (79)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">13 (68)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">40 (75)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02 shading" rowspan="1" colspan="1">Region — no. (%)</td><td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"></td><td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"></td><td align="left" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"></td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">United States</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">14 (41)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">8 (42)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">22 (42)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Japan</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">8 (24)</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">1 (5)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">9 (17)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Europe or Canada</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">12 (35)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">10 (53)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">22 (42)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02 shading" rowspan="1" colspan="1">Oxygen-support category — no. (%)</td><td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"></td><td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"></td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1"></td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Invasive ventilation</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">34 (100)</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">—</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">34 (64)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Invasive mechanical ventilation</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">30 (88)</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">—</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">30 (57)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Extracorporeal membrane oxygenation</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">4 (12)</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">—</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">4 (8)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Noninvasive oxygen support</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">—</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">19 (100)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">19 (36)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Noninvasive positive-pressure ventilation</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">—</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">2 (11)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">High-flow oxygen</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">—</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">5 (26)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">5 (9)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Low-flow oxygen</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">—</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">10 (53)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">10 (19)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Ambient air</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">—</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (11)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02" rowspan="1" colspan="1">Median duration of symptoms before remdesivir therapy (IQR) — days</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">11 (8–15)</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">13 (10–14)</td><td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1">12 (9–15)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02 shading" rowspan="1" colspan="1">Coexisting conditions — no. (%)</td><td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"></td><td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"></td><td align="left" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"></td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Any condition</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">25 (74)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">11 (58)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">36 (68)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Hypertension</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">9 (26)</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">4 (21)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">13 (25)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Diabetes</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">8 (24)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">1 (5)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">9 (17)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Hyperlipidemia</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">6 (18)</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">6 (11)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Asthma</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">5 (15)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">1 (5)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">6 (11)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02 shading" rowspan="1" colspan="1">Median laboratory values (IQR)</td><td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"></td><td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"></td><td align="left" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"></td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">ALT — IU per liter</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">48 (31–79)</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">27 (20–45)</td><td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1">37 (25–61)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">AST — IU per liter</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">39 (30–76)</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">35 (28–46)</td><td align="center" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1">36 (29–67)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xblx-borders hanging12" rowspan="1" colspan="1">Creatinine — mg per deciliter</td><td align="center" valign="top" content-type="entry xbxx-borders" rowspan="1" colspan="1">0.90 (0.66–1.17)</td><td align="center" valign="top" content-type="entry xbxx-borders" rowspan="1" colspan="1">0.79 (0.63–1.00)</td><td align="center" valign="top" content-type="entry xbxr-borders" rowspan="1" colspan="1">0.89 (0.64–1.08)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t1fn1"><label>*</label><p>ALT denotes alanine aminotransferase, AST aspartate aminotransferase, and IQR interquartile range. To convert the values for creatinine to micromoles per liter, multiply by 88.4.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Summary of Adverse Events.</title></caption><alternatives><graphic xlink:href="NEJMoa2007016_t2"></graphic><table frame="hsides" rules="groups" content-type="tgroup"><colgroup span="1"><col id="t2col1" width="49.94%" span="1"></col><col id="t2col2" width="16.68%" span="1"></col><col id="t2col3" width="16.68%" span="1"></col><col id="t2col4" width="16.68%" span="1"></col></colgroup><thead content-type="thead sticky"><tr content-type="row head1"><th align="left" valign="bottom" content-type="entry txlx-borders" rowspan="1" colspan="1">Event</th><th align="center" valign="bottom" content-type="entry txxx-borders" rowspan="1" colspan="1">Invasive Ventilation<break></break>(N=34)</th><th align="center" valign="bottom" content-type="entry txxx-borders" rowspan="1" colspan="1">Noninvasive Oxygen Support<break></break>(N=19)</th><th align="center" valign="bottom" content-type="entry txxr-borders" rowspan="1" colspan="1">Total<break></break>(N=53)</th></tr><tr content-type="row head3"><th align="left" content-type="entry xxlx-borders" rowspan="1" colspan="1"></th><th align="center" colspan="3" content-type="entry xxxr-borders" rowspan="1">number of patients (percent)</th></tr></thead><tbody content-type="tbody"><tr content-type="row head2"><td align="left" valign="bottom" content-type="entry xxlx-borders hanging02 shading" rowspan="1" colspan="1">Any adverse event</td><td valign="bottom" content-type="entry xxxx-borders hanging01 shading" align="char" char="(" rowspan="1" colspan="1">22 (65)</td><td valign="bottom" content-type="entry xxxx-borders hanging01 shading" align="char" char="(" rowspan="1" colspan="1">10 (53)</td><td valign="bottom" content-type="entry xxxr-borders hanging01 shading" align="char" char="(" rowspan="1" colspan="1">32 (60)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02" rowspan="1" colspan="1">Adverse events occurring in 2 or more patients</td><td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1"></td><td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1"></td><td content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1"></td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Hepatic enzyme increased<xref ref-type="table-fn" rid="t2fn1">*</xref></td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">8 (24)</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">4 (21)</td><td align="center" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1">12 (23)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Diarrhea</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">1 (3)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">4 (21)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">5 (9)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Rash</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (9)</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">1 (5)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">4 (8)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Renal impairment</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">4 (12)</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">4 (8)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Hypotension</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (9)</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">1 (5)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">4 (8)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Acute kidney injury</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">2 (6)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">1 (5)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">3 (6)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Atrial fibrillation</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (6)</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">1 (5)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (6)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Multiple-organ-dysfunction syndrome</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">3 (9)</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">3 (6)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Hypernatremia</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (9)</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (6)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Deep-vein thrombosis</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">3 (9)</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">3 (6)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Acute respiratory distress syndrome</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">1 (3)</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">1 (5)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Pneumothorax</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">2 (6)</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Hematuria</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (6)</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Delirium</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">1 (3)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">1 (5)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Septic shock</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (6)</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Pyrexia</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">1 (3)</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">1 (5)</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02 shading" rowspan="1" colspan="1">Any serious adverse event</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">9 (26)</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (16)</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">12 (23)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging02" rowspan="1" colspan="1">Serious events occurring in 2 or more patients</td><td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1"></td><td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1"></td><td content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1"></td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Multiple-organ-dysfunction syndrome</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (6)</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Septic shock</td><td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">2 (6)</td><td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Acute kidney injury</td><td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (6)</td><td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr><tr content-type="row"><td align="left" valign="top" content-type="entry xblx-borders hanging12" rowspan="1" colspan="1">Hypotension</td><td valign="top" content-type="entry xbxx-borders" align="char" char="(" rowspan="1" colspan="1">2 (6)</td><td align="center" valign="top" content-type="entry xbxx-borders" rowspan="1" colspan="1">0</td><td valign="top" content-type="entry xbxr-borders" align="char" char="(" rowspan="1" colspan="1">2 (4)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t2fn1"><label>*</label><p>Adverse-event terms are based on the <italic>Medical Dictionary for Regulatory Activities</italic>, version 22.1. Hepatic enzyme increased includes the following terms: hepatic enzyme increased, alanine aminotransferase increased, aspartate aminotransferase increased, and transaminases increased. Elevated hepatic enzymes resulted in discontinuation of remdesivir therapy in 2 patients.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001301 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001301 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7169476
|texte= Compassionate Use of Remdesivir for Patients with Severe Covid-19
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:NONE" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |